AMLX Q4 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$108M+395.5% YoY

Gross Profit

$99M91.4% margin

Operating Income

$2M1.8% margin

Net Income

$5M4.4% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$13M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$517M

Total Liabilities

$84M

Stockholders' Equity

$433M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$22M	+395.5%
Gross Profit	$99M	$19M	+419.8%
Operating Income	$2M	-$45M	+104.3%
Net Income	$5M	-$43M	+111.1%